Microbot Medical Launches Full U.S. Rollout of LIBERTY Robotic System
Event summary
- Microbot Medical begins full U.S. market release of LIBERTY Endovascular Robotic System at SIR Annual Meeting (April 11-15, 2026).
- System already adopted by multiple healthcare systems, including Emory Healthcare and Tampa General Hospital.
- Commercial team expanded from 4 to 8 sales territories, targeting 12 by year-end 2026.
- LIBERTY cleared for multiple procedures including PAE, UFE, GAE, and peripheral arterial interventions.
The big picture
Microbot's full market release comes as interventional radiology faces growing pressure to reduce radiation exposure and physical strain. The LIBERTY system's single-use, remotely operated design positions it as a potential disruptor in a market dominated by reusable surgical robots. The company's ability to scale its commercial footprint will be critical as it competes with established players in the $12B endovascular device market.
What we're watching
- Adoption Pace
- Whether the shorter sales cycle compared to traditional surgical robots will accelerate market penetration.
- Regulatory Tailwinds
- How new SIR/CIRSE guidelines on radiation protection may boost demand for LIBERTY's precision capabilities.
- Commercial Execution
- The effectiveness of the expanded sales team in converting SIR conference engagement into new installations.